Open Access

Erratum to: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

  • Trevor Powles1Email author,
  • Alexander Paterson2,
  • Eugene McCloskey3,
  • Phil Schein4,
  • Bobbi Scheffler5,
  • Alwynne Tidy6,
  • Sue Ashley6,
  • Ian Smith6,
  • Lars Ottestad7 and
  • John Kanis3
Breast Cancer Research20068:406

https://doi.org/10.1186/bcr1413

Published: 3 May 2006

The original article was published in Breast Cancer Research 2006 8:R13

It has been brought to our attention that there was a typographical error in our recent article [1] published in March 2006.

In the Conclusions section the final sentence should read:

Questions such as the optimal duration of therapy and efficacy in stage I disease remain to be answered.

Notes

Authors’ Affiliations

(1)
Parkside Oncology
(2)
Tom Baker Cancer Centre
(3)
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School
(4)
Department of Clinical Pharmacology, University of Oxford
(5)
Scheffler Group
(6)
Royal Marsden Hospital
(7)
Radium Institute

References

  1. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Research. 2006, 8: R13-10.1186/bcr1384.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© BioMed Central Ltd 2006

Advertisement